Chapter title |
Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders
|
---|---|
Chapter number | 4 |
Book title |
Proteomic Methods in Neuropsychiatric Research
|
Published in |
Advances in experimental medicine and biology, March 2017
|
DOI | 10.1007/978-3-319-52479-5_4 |
Pubmed ID | |
Book ISBNs |
978-3-31-952478-8, 978-3-31-952479-5
|
Authors |
Hassan Rahmoune, Daniel Martins-de-Souza, Paul C. Guest |
Editors |
Paul C. Guest |
Abstract |
Proteomic-based biomarkers are now an integral part of the drug development process. This chapter covers the role of proteomic biomarker tests as useful tools for improving preclinical research and clinical development. One medical area that has been lagging behind this process is the study of psychiatric disorders, and this is most likely due to the complexity of these diseases. The potential of incorporating biomarkers in the clinical pipeline to improve decision-making, accelerate drug development, improve translation and reduce development costs is also discussed, with a focus on psychiatric diseases like schizophrenia. This chapter will also discuss the next steps that must be taken to keep moving this process forwards. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 23% |
Researcher | 3 | 23% |
Student > Ph. D. Student | 1 | 8% |
Student > Doctoral Student | 1 | 8% |
Student > Master | 1 | 8% |
Other | 1 | 8% |
Unknown | 3 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 38% |
Business, Management and Accounting | 1 | 8% |
Psychology | 1 | 8% |
Nursing and Health Professions | 1 | 8% |
Decision Sciences | 1 | 8% |
Other | 1 | 8% |
Unknown | 3 | 23% |